[시장보고서]치료용 혈장 교환 시장 : 세계 업계 분석, 규모, 점유율, 수량, 성장, 동향, 예측(2023-2031년)

치료용 혈장 교환 시장 : 세계 업계 분석, 규모, 점유율, 수량, 성장, 동향, 예측(2023-2031년)

Therapeutic Plasma Exchange Market (Disease Indication: Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders, and Others) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast, 2023-2031

상품코드 : 1420921

리서치사 : Transparency Market Research

발행일 : 2023년 12월

페이지 정보 : 영문 161 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,630,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 13,098,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,566,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

치료용 혈장 교환 시장 - 보고서 범위

세계의 치료용 혈장 교환 시장에 관한 TMR의 보고서는 과거와 현재의 성장 동향 및 2023년부터 2031년까지의 예측기간 동안 시장 지표의 귀중한 인사이트를 얻을 수 있는 기회를 연구하고 있습니다. 2023년을 기준 연도, 2031년을 예측 연도로 삼아 2017년부터 2031년까지의 세계 시장 매출을 제공합니다. 또한 2023년부터 2031년까지 연평균 성장률(CAGR %)도 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 이루어지고, 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 메이커와의 인터뷰를 실시했습니다. 2차 조사에는 치료용 혈장 교환 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차 보고서, 프레스 릴리스 및 관련 문서에 대한 참조가 포함됩니다.

시장 현황
2023년 시장 가치	15억 달러
2031년 시장 가치	29억 달러
CAGR	7.5%

이 보고서는 세계의 치료용 혈장 교환 시장 경쟁 상황을 자세히 살펴봅니다. 세계의 치료용 혈장 교환 시장에서 활동하는 주요 기업이 확인되었으며, 이들 각각이 다양한 속성의 관점에서 프로파일링됩니다. 기업 개요, 재무 상황, 최근의 동향, SWOT는 이 보고서에서 소개되고 있는 세계의 치료용 혈장 교환 시장 기업의 속성입니다.

서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 질환 적응증별, 2023-2031
- 신경학적 장애
  - 만성 염증성 탈수초성 다발성 신경병증
  - 중증 근무력증
  - 다발성 경화증
  - 시신경 척수염
  - 길랭 바레 증후군
- 신장질환
  - 신장 이식후 거부 반응
  - 항사구체 기저막(GBM) 질환
  - 웨게너 육아종증
- 혈액질환
  - 혈전성 혈소판 감소성 자반증
  - 용혈성 요독 증후군
  - 한랭글로불린혈증
  - 다발성 골수종
  - 대사장애
  - 동형접합 가족성 고콜레스테롤혈증
  - 전격성 윌슨병
- 기타
시장 매력 분석 : 질환 적응증별

제7장 세계 시장 분석과 예측 : 최종사용자별

서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 최종사용자별, 2023-2031
- 병원
- 전문 클리닉
- 외래 수술 센터
시장 매력도 분석 : 최종사용자별

제8장 세계 시장 분석과 예측 : 지역별

주요 조사 결과
시장 금액 예측 : 지역별, 2023-2031
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
시장 매력도 분석 : 지역별

제9장 북미 시장 분석과 예측

제10장 유럽 시장 분석과 예측

제11장 아시아태평양 시장 분석과 예측

제12장 라틴아메리카 시장 분석과 예측

제13장 중동 및 아프리카 시장 분석과 예측

제14장 경쟁 상황

시장 기업 - 경쟁 매트릭스(기업 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
- Asahi Kasei Corporation
- Baxter International, Inc.
- Terumo Corporation
- B. Braun SE
- Fresenius Kabi AG
- SB-Kawasumi Laboratories, Inc.
- Haemonetics Corporation
- Cerus Corporation
- Charles River Laboratories
- Medica SpA

KSM

영문 목차

영문목차

Therapeutic Plasma Exchange Market - Scope of Report

TMR's report on the global therapeutic plasma exchange market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global therapeutic plasma exchange market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global therapeutic plasma exchange market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the therapeutic plasma exchange market.

Market Snapshot
Market Value in 2023	US$ 1.5 Bn
Market Value in 2031	US$ 2.9 Bn
CAGR	7.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global therapeutic plasma exchange market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global therapeutic plasma exchange market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global therapeutic plasma exchange market.

The report delves into the competitive landscape of the global therapeutic plasma exchange market. Key players operating in the global therapeutic plasma exchange market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global therapeutic plasma exchange market profiled in this report.

Key Questions Answered in Global therapeutic plasma exchange Market Report:

What is the sales/revenue generated by therapeutic plasma exchange across all regions during the forecast period?
What are the opportunities in the global therapeutic plasma exchange market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Therapeutic Plasma Exchange Market - Research Objectives and Research Approach

The comprehensive report on the global therapeutic plasma exchange market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global therapeutic plasma exchange market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global therapeutic plasma exchange market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Therapeutic Plasma Exchange Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Therapeutic Plasma Exchange Market Analysis and Forecast, 2023-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Disease Indication

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Indication, 2023-2031
- 6.3.1. Neurological Disorders
  - 6.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
  - 6.3.1.2. Myasthenia Gravis
  - 6.3.1.3. Multiple Sclerosis
  - 6.3.1.4. Neuromyelitis Optica
  - 6.3.1.5. Guillain-Barre Syndrome
- 6.3.2. Renal Disorders
  - 6.3.2.1. Post-renal Transplant Rejection
  - 6.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
  - 6.3.2.3. Wegener's Granulomatosis
- 6.3.3. Hematology Disorders
  - 6.3.3.1. Thrombotic Thrombocytopenic Purpura
  - 6.3.3.2. Hemolytic Uremic Syndrome
  - 6.3.3.3. Cryoglobulinemia
  - 6.3.3.4. Multiple Myeloma
  - 6.3.3.5. Metabolic Disorders
  - 6.3.3.6. Homozygous Familial Hypercholesterolemia
  - 6.3.3.7. Fulminant Wilson's Disease
- 6.3.4. Others
6.4. Market Attractiveness Analysis, by Disease Indication

7. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by End-user

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2023-2031
- 7.3.1. Hospitals
- 7.3.2. Specialty Clinics
- 7.3.3. Ambulatory Surgical Centers
7.4. Market Attractiveness Analysis, by End-user

8. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Region

8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023-2031
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Therapeutic Plasma Exchange Market Analysis and Forecast

9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Disease Indication, 2023-2031
- 9.3.1. Neurological Disorders
  - 9.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
  - 9.3.1.2. Myasthenia Gravis
  - 9.3.1.3. Multiple Sclerosis
  - 9.3.1.4. Neuromyelitis Optica
  - 9.3.1.5. Guillain-Barre Syndrome
- 9.3.2. Renal Disorders
  - 9.3.2.1. Post-renal Transplant Rejection
  - 9.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
  - 9.3.2.3. Wegener's Granulomatosis
- 9.3.3. Hematology Disorders
  - 9.3.3.1. Thrombotic Thrombocytopenic Purpura
  - 9.3.3.2. Hemolytic Uremic Syndrome
  - 9.3.3.3. Cryoglobulinemia
  - 9.3.3.4. Multiple Myeloma
  - 9.3.3.5. Metabolic Disorders
  - 9.3.3.6. Homozygous Familial Hypercholesterolemia
  - 9.3.3.7. Fulminant Wilson's Disease
- 9.3.4. Others
9.4. Market Value Forecast, by End-user, 2023-2031
- 9.4.1. Hospitals
- 9.4.2. Specialty Clinics
- 9.4.3. Ambulatory Surgical Centers
9.5. Market Value Forecast, by Country, 2023-2031
- 9.5.1. U.S.
- 9.5.2. Canada
9.6. Market Attractiveness Analysis
- 9.6.1. By Disease Indication
- 9.6.2. By End-user
- 9.6.3. By Country

10. Europe Therapeutic Plasma Exchange Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Indication, 2023-2031
- 10.3.1. Neurological Disorders
  - 10.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
  - 10.3.1.2. Myasthenia Gravis
  - 10.3.1.3. Multiple Sclerosis
  - 10.3.1.4. Neuromyelitis Optica
  - 10.3.1.5. Guillain-Barre Syndrome
- 10.3.2. Renal Disorders
  - 10.3.2.1. Post-renal Transplant Rejection
  - 10.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
  - 10.3.2.3. Wegener's Granulomatosis
- 10.3.3. Hematology Disorders
  - 10.3.3.1. Thrombotic Thrombocytopenic Purpura
  - 10.3.3.2. Hemolytic Uremic Syndrome
  - 10.3.3.3. Cryoglobulinemia
  - 10.3.3.4. Multiple Myeloma
  - 10.3.3.5. Metabolic Disorders
  - 10.3.3.6. Homozygous Familial Hypercholesterolemia
  - 10.3.3.7. Fulminant Wilson's Disease
- 10.3.4. Others
10.4. Market Value Forecast, by End-user, 2023-2031
- 10.4.1. Hospitals
- 10.4.2. Specialty Clinics
- 10.4.3. Ambulatory Surgical Centers
- 10.4.4. Others
10.5. Market Value Forecast, by Country/Sub-region, 2023-2031
- 10.5.1. Germany
- 10.5.2. U.K.
- 10.5.3. France
- 10.5.4. Italy
- 10.5.5. Spain
- 10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
- 10.6.1. By Disease Indication
- 10.6.2. By End-user
- 10.6.3. By Country/Sub-region

11. Asia Pacific Therapeutic Plasma Exchange Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Indication, 2023-2031
- 11.3.1. Neurological Disorders
  - 11.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
  - 11.3.1.2. Myasthenia Gravis
  - 11.3.1.3. Multiple Sclerosis
  - 11.3.1.4. Neuromyelitis Optica
  - 11.3.1.5. Guillain-Barre Syndrome
- 11.3.2. Renal Disorders
  - 11.3.2.1. Post-renal Transplant Rejection
  - 11.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
  - 11.3.2.3. Wegener's Granulomatosis
- 11.3.3. Hematology Disorders
  - 11.3.3.1. Thrombotic Thrombocytopenic Purpura
  - 11.3.3.2. Hemolytic Uremic Syndrome
  - 11.3.3.3. Cryoglobulinemia
  - 11.3.3.4. Multiple Myeloma
  - 11.3.3.5. Metabolic Disorders
  - 11.3.3.6. Homozygous Familial Hypercholesterolemia
  - 11.3.3.7. Fulminant Wilson's Disease
- 11.3.4. Others
11.4. Market Value Forecast, by End-user, 2023-2031
- 11.4.1. Hospitals
- 11.4.2. Specialty Clinics
- 11.4.3. Ambulatory Surgical Centers
- 11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2023-2031
- 11.5.1. China
- 11.5.2. Japan
- 11.5.3. India
- 11.5.4. Australia & New Zealand
- 11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
- 11.6.1. By Disease Indication
- 11.6.2. By End-user
- 11.6.3. By Country/Sub-region

12. Latin America Therapeutic Plasma Exchange Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Indication, 2023-2031
- 12.3.1. Neurological Disorders
  - 12.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
  - 12.3.1.2. Myasthenia Gravis
  - 12.3.1.3. Multiple Sclerosis
  - 12.3.1.4. Neuromyelitis Optica
  - 12.3.1.5. Guillain-Barre Syndrome
- 12.3.2. Renal Disorders
  - 12.3.2.1. Post-renal Transplant Rejection
  - 12.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
  - 12.3.2.3. Wegener's Granulomatosis
- 12.3.3. Hematology Disorders
  - 12.3.3.1. Thrombotic Thrombocytopenic Purpura
  - 12.3.3.2. Hemolytic Uremic Syndrome
  - 12.3.3.3. Cryoglobulinemia
  - 12.3.3.4. Multiple Myeloma
  - 12.3.3.5. Metabolic Disorders
  - 12.3.3.6. Homozygous Familial Hypercholesterolemia
  - 12.3.3.7. Fulminant Wilson's Disease
- 12.3.4. Others
12.4. Market Value Forecast, by End-user, 2023-2031
- 12.4.1. Hospitals
- 12.4.2. Specialty Clinics
- 12.4.3. Ambulatory Surgical Centers
- 12.4.4. Others
12.5. Market Value Forecast, by Country/Sub-region, 2023-2031
- 12.5.1. Brazil
- 12.5.2. Mexico
- 12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
- 12.6.1. By Disease Indication
- 12.6.2. By End-user
- 12.6.3. By Country/Sub-region

13. Middle East & Africa Therapeutic Plasma Exchange Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Indication, 2023-2031
- 13.3.1. Neurological Disorders
  - 13.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
  - 13.3.1.2. Myasthenia Gravis
  - 13.3.1.3. Multiple Sclerosis
  - 13.3.1.4. Neuromyelitis Optica
  - 13.3.1.5. Guillain-Barre Syndrome
- 13.3.2. Renal Disorders
  - 13.3.2.1. Post-renal Transplant Rejection
  - 13.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
  - 13.3.2.3. Wegener's Granulomatosis
- 13.3.3. Hematology Disorders
  - 13.3.3.1. Thrombotic Thrombocytopenic Purpura
  - 13.3.3.2. Hemolytic Uremic Syndrome
  - 13.3.3.3. Cryoglobulinemia
  - 13.3.3.4. Multiple Myeloma
  - 13.3.3.5. Metabolic Disorders
  - 13.3.3.6. Homozygous Familial Hypercholesterolemia
  - 13.3.3.7. Fulminant Wilson's Disease
- 13.3.4. Others
13.4. Market Value Forecast, by End-user, 2023-2031
- 13.4.1. Hospitals
- 13.4.2. Specialty Clinics
- 13.4.3. Ambulatory Surgical Centers
- 13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2023-2031
- 13.5.1. GCC Countries
- 13.5.2. South Africa
- 13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
- 13.6.1. By Disease Indication
- 13.6.2. By End-user
- 13.6.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
- 14.3.1. Asahi Kasei Corporation
  - 14.3.1.1. Company Overview
  - 14.3.1.2. Product Portfolio
  - 14.3.1.3. SWOT Analysis
  - 14.3.1.4. Financial Overview
  - 14.3.1.5. Strategic Overview
- 14.3.2. Baxter International, Inc.
  - 14.3.2.1. Company Overview
  - 14.3.2.2. Product Portfolio
  - 14.3.2.3. SWOT Analysis
  - 14.3.2.4. Financial Overview
  - 14.3.2.5. Strategic Overview
- 14.3.3. Terumo Corporation
  - 14.3.3.1. Company Overview
  - 14.3.3.2. Product Portfolio
  - 14.3.3.3. SWOT Analysis
  - 14.3.3.4. Financial Overview
  - 14.3.3.5. Strategic Overview
- 14.3.4. B. Braun SE
  - 14.3.4.1. Company Overview
  - 14.3.4.2. Product Portfolio
  - 14.3.4.3. SWOT Analysis
  - 14.3.4.4. Financial Overview
  - 14.3.4.5. Strategic Overview
- 14.3.5. Fresenius Kabi AG
  - 14.3.5.1. Company Overview
  - 14.3.5.2. Product Portfolio
  - 14.3.5.3. SWOT Analysis
  - 14.3.5.4. Financial Overview
  - 14.3.5.5. Strategic Overview
- 14.3.6. SB-Kawasumi Laboratories, Inc.
  - 14.3.6.1. Company Overview
  - 14.3.6.2. Product Portfolio
  - 14.3.6.3. SWOT Analysis
  - 14.3.6.4. Financial Overview
  - 14.3.6.5. Strategic Overview
- 14.3.7. Haemonetics Corporation
  - 14.3.7.1. Company Overview
  - 14.3.7.2. Product Portfolio
  - 14.3.7.3. SWOT Analysis
  - 14.3.7.4. Financial Overview
  - 14.3.7.5. Strategic Overview
- 14.3.8. Cerus Corporation
  - 14.3.8.1. Company Overview
  - 14.3.8.2. Product Portfolio
  - 14.3.8.3. SWOT Analysis
  - 14.3.8.4. Financial Overview
  - 14.3.8.5. Strategic Overview
- 14.3.9. Charles River Laboratories
  - 14.3.9.1. Company Overview
  - 14.3.9.2. Product Portfolio
  - 14.3.9.3. SWOT Analysis
  - 14.3.9.4. Financial Overview
  - 14.3.9.5. Strategic Overview
- 14.3.10. Medica S.p.A.
  - 14.3.10.1. Company Overview
  - 14.3.10.2. Product Portfolio
  - 14.3.10.3. SWOT Analysis
  - 14.3.10.4. Financial Overview
  - 14.3.10.5. Strategic Overview